Download
s00415-019-09681-7.pdf 982,96KB
WeightNameValue
1000 Titel
  • Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study
1000 Autor/in
  1. Hefter, Harald |
  2. Brauns, Raphaela |
  3. Ürer, Beyza |
  4. Rosenthal, Dietmar |
  5. Albrecht, Philipp |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-01-20
1000 Erschienen in
1000 Quellenangabe
  • 267(5):1340-1347
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00415-019-09681-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184051/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Among the spectrum of licensed botulinum neurotoxin preparations incobotulinumtoxin (incoBoNT/A; Xeomin®) is the only one which does not contain complex proteins. Therefore, incoBoNT/A has been suggested to have a low antigenicity, but precise estimations on incidence and prevalence of neutralizing antibody formation during long-term treatment are outstanding so far.!##!Methods!#!For the present cross-sectional study, 59 patients having exclusively been treated with incoBoNT/A (mono group) and 32 patients having been treated with other BoNT/A preparations less than nine times and who were then switched to at least 14 sessions of incoBoNT/A treatment (switch group) were recruited from one botulinum toxin outpatient clinic. Side effects and doses were extracted from the charts, and the efficacy of treatment was assessed by the patients using a visual analogue scale (0-100). The prevalence of neutralizing antibodies was tested by means of the mouse hemi-diaphragm assay (MHDA).!##!Findings!#!None of the patients in the mono and only two in the switch group had a positive MHDA-test. Across all indications and patients, mean improvement exceeded 67%. Improvement did not depend on age at onset, sex, change of dose or duration of treatment, but on disease entity. In patients with cervical dystonia, improvement was about the same in the mono and switch subgroup, but the last dose was different.!##!Conclusions!#!The present study confirms the low antigenicity of incoBoNT/A, which has immediate consequences for patient management, and the use of higher doses and shorter durations of reinjection intervals in botulinum toxin therapy.
1000 Sacherschließung
lokal Complex proteins
lokal Dystonia/drug therapy [MeSH]
lokal Aged [MeSH]
lokal Muscular Diseases/drug therapy [MeSH]
lokal Antibodies, Neutralizing/blood [MeSH]
lokal Blepharospasm/drug therapy [MeSH]
lokal Male [MeSH]
lokal Neuromuscular Agents/administration
lokal Neutralizing antibodies
lokal Botulinum Toxins, Type A/administration
lokal Neuromuscular Agents/immunology [MeSH]
lokal Female [MeSH]
lokal Muscle Spasticity/drug therapy [MeSH]
lokal Botulinum Toxins, Type A/immunology [MeSH]
lokal Incobotulinumtoxin
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Cross-Sectional Studies [MeSH]
lokal Animals [MeSH]
lokal Mice [MeSH]
lokal Long-term treatment
lokal Original Communication
lokal Low antigenicity
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-1069-7684|https://frl.publisso.de/adhoc/uri/QnJhdW5zLCBSYXBoYWVsYQ==|https://frl.publisso.de/adhoc/uri/w5xyZXIsIEJleXph|https://frl.publisso.de/adhoc/uri/Um9zZW50aGFsLCBEaWV0bWFy|https://frl.publisso.de/adhoc/uri/QWxicmVjaHQsIFBoaWxpcHA=
1000 Hinweis
  • DeepGreen-ID: 9e14698257a546788e373d28b39931a6 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6469646.rdf
1000 Erstellt am 2023-11-18T00:26:16.144+0100
1000 Erstellt von 322
1000 beschreibt frl:6469646
1000 Zuletzt bearbeitet 2023-12-01T10:15:18.687+0100
1000 Objekt bearb. Fri Dec 01 10:15:18 CET 2023
1000 Vgl. frl:6469646
1000 Oai Id
  1. oai:frl.publisso.de:frl:6469646 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source